Upadacitinib

Drug Profile

Upadacitinib

Alternative Names: ABT-494

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Atopic dermatitis; Crohn's disease

Most Recent Events

  • 09 Jun 2017 AbbVie plans a phase IIb/III trial for Ankylosing spondylitis in USA (NCT03178487)
  • 07 Jun 2017 Safety and efficacy data from the phase III SELECT-NEXT trial in Rheumatoid Arthritis released by AbbVie
  • 09 May 2017 Phase-III clinical trials in Rheumatoid arthritis (Treatment-experienced) in Canada, Hungary, Germany, Latvia, Portugal, Belgium, Spain (PO) (EudraCT2016-000933-37; NCT03086343)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top